Novo Nordisk (NVO.US) plans to seek regulatory approval in the United States for high-dose Wegovy.

Zhijun Finance and Economics APP learned that Novo Nordisk (NVO.US) plans to apply for regulatory approval in the United States for a high-dose version of its blockbuster weight loss therapy "Wegovy." This is another important move by the company in the booming obesity treatment market to compete against its strong rival Eli Lilly (LLY.US).